| Stereochemistry | ACHIRAL |
| Molecular Formula | C20H29N5O3 |
| Molecular Weight | 387.476 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCCCNC(=O)NC1CCN(CC1)C2=C3C=C(OC)C(OC)=CC3=NC=N2
InChI
InChIKey=CPZHDDGPHQRMEJ-UHFFFAOYSA-N
InChI=1S/C20H29N5O3/c1-4-5-8-21-20(26)24-14-6-9-25(10-7-14)19-15-11-17(27-2)18(28-3)12-16(15)22-13-23-19/h11-14H,4-10H2,1-3H3,(H2,21,24,26)
Buquineran (UK14275), an inotropic compound, is a coronary vasolidator agent. It has been shown to exert a
powerful inotropic effect with minimal effect on heart rate in dogs. Buquineran is a phosphodiesterase inhibitor. It acted as potent inhibitor of cyclic AMP hydrolysis catalysed by both PDE-II and PDE-III enzymes.
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
| 7.6 µM [IC50] |
PubMed
Patents
Sample Use Guides
Electrophysiological and haemodynamic measurements were made in six dogs over
successive 30 min periods under control conditions and during infusion of Buquineran at 50,
100 and 250 ug/kg per min (infusion rates 0.91, 1.82 and 4.55 ml/min), respectively.
Route of Administration:
Intravenous
ACTIVE MOIETY
